Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
Conditions: Neuroendocrine Tumors; Carcinoid Syndrome Intervention: Drug: Sandostatin Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Terminated
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials